Clinical Utility of Decipher
Because Decipher can independently predict metastatic behavior in PCa patients, clinicians can make preliminary treatment decisions by differentiating between low and high-risk individuals, preferentially treating those predicted with high GC scores 40. In comparison, Gleason scores, PSA levels, and other qualitative features of PCa do not adequately distinguish the risk of continued PCa progression and thereby does not offer a proper identification of low and high-risk PCa patients. By stratifying patients based on their GC score, personal treatment can be subsequently established. Patients with low GC scores do not necessitate aggressive PCa treatment options such as postoperative radiation, but those with higher GC scores can immediately be benefitted by aggressive secondary therapy when identified44 45.